Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Sarah Paul et al.|Nature Medicine|2018Cited by 1.2k
Comprehensive Analysis of Hypermutation in Human CancerBrittany Campbell, Melyssa Aronson, Scott Davidson et al.|Cell|2017Cited by 795
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B. Johnson, Christine M. Lovly, Garrett M. Frampton et al.|Cancer Immunology Research|2016Cited by 493